Stay updated with breaking news from Cellular Therapy Service. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amtagvi is the first tumour-derived autologous T cell immunotherapy therapy to be approved by the US Food and Drug Administration for certain adults with unresectable or metastatic...
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune...
Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma—even in those with high-risk features.
Roisin E. O'Cearbhaill, MD, discusses key findings from a phase 1/2 dose escalation study of ubamatamab plus cemiplimab in recurrent ovarian cancer.
/PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for...